Article
Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
British journal of haematology - 1 Aug 2015
Falini Brunangelo, Sportoletti Paolo, Brunetti Lorenzo, Martelli Maria Paola
Abstract excerpt
The acute myeloid leukaemia (AML) genome contains more than 20 driver recurrent mutations. Here, we review the potential for therapeutic targeting of the most common mutations associated with normal cytogenetics AML, focusing on those affecting the FLT3, NPM1 and epigenetic modifier genes (DNMT3A, IDH1/2, TET2). As compared to early compounds, second generation FLT3 inhibitors are more specific and have better...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.